

Aviso de Derechos para emisoras del

FECHA: 02/07/2025



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	267109
FOLIO DE REFERENCIA INDEVAL	825561C001
TIPO DE MENSAJE	NEW
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	PROK
RAZÓN SOCIAL	PROKIDNEY CORP.
SERIE	N
ISIN	KYG7S53R1049
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	EXCHANGE
-----------------------	----------

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
FECHA EFECTOS	01/07/2025

OPCIÓN	1
TIPO	Security
DEFAULT	true

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

Aviso de Derechos para emisoras del

FECHA: 02/07/2025



VALORES A RECIBIR	
	KYG7S53R1049
TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	1 / 1
VALORES A RECIBIR	NewIssue
	US74291D1046

NOTAS DEL EVENTO CORPORATIVO

NOTA
(02/07/2025)
Press Release July 1, 2025 ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of ProKidney. ProKidney common stock will begin trading on July 2, 2025, and the Company's trading symbol on the Nasdaq Stock Market will remain unchanged as "PROK." The Company's CUSIP number relating to its Class A common stock changed to 74291D104. The Company does not anticipate any impact to day-to-day business operations as a result of the domestication.